3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Lymphocytic, Chronic, B-Cell
3
Neoplasms
2
Hematologic Neoplasms
2
Rare Diseases
1
Neurologic Manifestations
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Myasthenia Gravis
1
Mental Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia
1
Infections
1
Burkitt Lymphoma
1
Agammaglobulinemia
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
92
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
52
Doxorubicin
50
trametinib
47
atezolizumab
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
Immunoglobulins
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled
NCT02343211
2017-11-06
IaSON
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
17 enrolled